"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D014230
|
| MeSH Number(s) |
D03.383.129.799
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2002 | 2 | 0 | 2 |
| 2003 | 4 | 1 | 5 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 4 | 7 |
| 2014 | 0 | 3 | 3 |
| 2015 | 4 | 3 | 7 |
| 2016 | 2 | 6 | 8 |
| 2017 | 6 | 3 | 9 |
| 2018 | 2 | 3 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 5 | 5 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
-
Clearance of HIV infection by selective elimination of host cells capable of producing HIV. Nat Commun. 2020 08 13; 11(1):4051.
-
Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J Clin Invest. 2020 04 01; 130(4):1782-1792.
-
Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole. Pediatr Infect Dis J. 2020 04; 39(4):310-312.
-
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun. 2018 09 19; 9(1):3815.
-
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels. Antimicrob Agents Chemother. 2017 04; 61(4).
-
AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.
-
BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct; 13(10):2315-27.
-
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20; 32(12):1202-9.
-
Prevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 2014 Mar; 11(3):127-8.